Compare Amgen, Inc. (AMGN) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Goldman Sachs Group Inc — how do they compare? Amgen, Inc. trades at $360.83 (market cap $196.12B), while Goldman Sachs Group Inc trades at $1,046.12 (market cap $311.29B). The key difference: Goldman Sachs Group Inc is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | GS | |
|---|---|---|
Market Cap | $196.12B | $311.29B |
Sector | Health | Financials |
52-Week High | $388.16 | $1.11K |
52-Week Low | $271.18 | $700.41 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 1.71% |
Volume | — | 2,592,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Goldman Sachs (GS) trades at $1,055.18, down 0.07% on the day, with a bullish technical outlook supported by moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $17.55 exceeding expectations. Revenue growth accelerated to $58.28 billion in 2025, and net income margin improved to 29.89%. Recent news highlights GS's role in leading high-profile IPOs, including Anthropic, signaling robust investment banking momentum.
The stock presents a favorable risk-reward profile with a consensus price target of $1,080, implying modest upside. Strengths include earnings momentum and leadership in M&A, but risks involve volatile cash flows and macroeconomic sensitivity. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
